AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference

AbbVie NYSE: ABBV executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit its long-term strategy.

MarketBeat • 9 hours ago

AbbVie Inc. (ABBV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

AbbVie Inc. (ABBV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha • 7 hours ago

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

Pharmaceutical giant AbbVie has a longer history of dividend growth than Pfizer. Pfizer faces greater exposure this decade to the loss of patent exclusivity for its blockbuster drugs.

The Motley Fool • Sep 8, 2026

AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note

In the most recent trading session, AbbVie (ABBV) closed at $248.78, indicating a -2.99% shift from the previous trading day.

Zacks Investment Research • Sep 8, 2026

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.

MarketBeat • Sep 6, 2026

3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)

AbbVie is a Dividend King that has proven its resilience. Enbridge appears to have a straightforward path to delivering double-digit total returns.

The Motley Fool • Sep 5, 2026

Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

Market Watch • Sep 5, 2026

AbbVie's Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?

AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.

24/7 Wall Street • Sep 4, 2026

AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)

AbbVie remains a 'Buy', supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. The recent $11B Apogee Therapeutics acquisition enhances ABBV's pipeline in immunology, oncology, neuroscience, and aesthetics, with only modest near-term EPS dilution. Q2 results beat expectations, driven by Skyrizi and Rinvoq, while technicals and momentum favor continued upside toward a $292 price target.

Seeking Alpha • Sep 4, 2026

ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study

AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.

Zacks Investment Research • Sep 4, 2026